• ABPI Website
  • Media
  • 10-year Moderna deal underlines UK potential for global life science leadership

10-year Moderna deal underlines UK potential for global life science leadership

The partnership with Moderna will see a new Innovation and Technology Centre in the UK, which will create more than 150 highly skilled jobs and have the capacity to produce up to 250 million vaccines per year in the event of a pandemic.

The state-of-the-art mRNA vaccine research and manufacturing facility will help to provide UK patients with access to the next generation of mRNA vaccines and treatments.

Commenting on the announcement, Richard Torbett, Chief Executive, ABPI said:

“This partnership is fantastic news for British manufacturing and UK-based science and research. It is an important reminder that the Life Sciences Industry has the potential to be a key growth driver for the UK economy.

“The pharmaceutical industry already invests more than any other sector in R&D in the UK, driving the discovery of the next generation of medicines and vaccines. As this deal shows, with the right support and backing from government, our industry can drive forward innovation-led growth, and deliver the high quality, high value jobs our economy needs.”

  • #ValuingVaccines
  • Clinical research
  • Research and Development
  • Manufacturing

Last modified: 20 September 2023

Last reviewed: 20 September 2023

The ABPI exists to make the UK the best place in the world to research, develop and use new medicines. We represent companies of all sizes who invest in discovering the medicines of the future. 

Our members supply cutting edge treatments that improve and save the lives of millions of people. We work in partnership with Government and the NHS so patients can get new treatments faster and the NHS can plan how much it spends on medicines. Every day, we partner with organisations in the life sciences community and beyond to transform lives across the UK.